CN Patent

CN102770131A — 卡巴他赛的新颖抗肿瘤用途

Assigned to Aventis Pharma SA · Expires 2012-11-07 · 14y expired

What this patent protects

本发明涉及可呈碱形式或呈水合物或溶剂化物形式的下面式(I)化合物，其与泼尼松或泼尼松龙组合，其在治疗前列腺癌特别是转移性前列腺癌中用作药物，尤其是用于不适于接受基于紫杉烷的治疗的患者。

USPTO Abstract

本发明涉及可呈碱形式或呈水合物或溶剂化物形式的下面式(I)化合物，其与泼尼松或泼尼松龙组合，其在治疗前列腺癌特别是转移性前列腺癌中用作药物，尤其是用于不适于接受基于紫杉烷的治疗的患者。

Drugs covered by this patent

Patent Metadata

Patent number
CN102770131A
Jurisdiction
CN
Classification
—
Expires
2012-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.